MCM
AKBA icon

MAI Capital Management’s Akebia Therapeutics AKBA Stock Holding History

MAI Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$572 Buy
+411
New +$565 ﹤0.01% 4370

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

MAI Capital Management's AKBA Position: Q1 2026 in Review

MAI Capital Management opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 411 shares worth $572. The stake represents ﹤0.01% of the portfolio and ranks #4370 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • MAI Capital Management held 411 shares of Akebia Therapeutics worth $572 as of Q1 2026.
  • Akebia Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4370 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.